Gujarat's Senores Pharma, via its US arm, is acquiring 14 ANDAs from Dr. Reddy's Labs, comprising 13 approved and one pending drug. This deal, valued at a $421 million market opportunity in the US, uses IPO funds. The acquisition aims to boost Senores' footprint in the US generics market.